Interview
The science that could keep us healthy in our 80s and beyond | Laura Deming
- Regulatory Milestone: The FDA recently accepted efficacy data for a lifespan extension drug in dogs (developed by the company Loyal), a breakthrough Laura Deming describes as "impossible" five years prior to the achievement.
- This marks the first time a regulatory body has considered "lifespan extension" as a valid drug indication, even though the drug is not yet fully approved pending safety and manufacturing reviews.
- Deming views this as a critical validation for the entire field, regardless of whether the specific dog drug ultimately succeeds in clinical trials.
- Scientific Feasibility of Lifespan Extension: Deming argues that lifespan is a malleable parameter, supported by empirical evidence in model organisms that contradicts previous assumptions of fixed limits.
- Genetic Mutations: Single gene mutations in worms (e.g., daf-2) have been shown to extend lifespan by a factor of two; applying the same gene modification in mice also results in significantly longer lifespans.
- Drug Interventions: Administering existing FDA-approved drugs like rapamycin and metformin to mice has increased lifespan by approximately 110% and 106%, respectively, though the exact mechanisms remain partially theoretical.
- Cellular Interventions: Removing senescent (aged, non-dividing) cells from mice has increased their lifespan by 135%, demonstrating that targeting specific cell populations can alter aging trajectories.
- Partial Reprogramming: Expressing Yamanaka factors (proteins that reprogram cells to a younger state) in mice has shown anti-aging effects, though improper application carries cancer risks.
- Parabiosis: Surgically joining the circulatory systems of old and young mice has resulted in health improvements in the older subjects, suggesting systemic factors in blood influence aging.
- Future Projections and Timeline: Deming does not expect humans to live for thousands of years within the next few decades but predicts a trajectory of increasing agency over health.
- Near-Term (Next Decade): Plausible availability of FDA-approved lifespan extension drugs for dogs; potential demonstration of small (months to years) lifespan extensions in humans.
- Mid-Term (Next 20-30 Years): Development of therapies that provide "enormously more agency" for individuals over 50 to pursue second careers, education, or artistic endeavors by reversing physical decline.
- Long-Term Goal: The primary objective is to shift the default societal belief that aging is inevitable to one where chronological age is not a risk factor for health.
- Addressing Common Objections: Deming systematically counters philosophical and practical objections to longevity research.
- Immortality vs. Agency: No current or proposed medicine guarantees immortality; the goal is to provide individuals with the choice to live longer or choose to die, rather than eliminating death entirely.
- Meaning of Life: Deming argues that "death gives life meaning" is not a sufficient reason to halt medical progress, as the potential for increased human flourishing, discovery, and extended relationships outweighs the risk of potential boredom.
- Overpopulation/Environmental Impact: She maintains that population growth is a solvable problem through technology and that withholding life-extending medicine due to uncertain future scenarios is ethically unjustifiable.
- Digital Uploading: Deming prioritizes biological longevity over digital consciousness uploading, citing the high risk that digital transitions may not preserve identity continuity and the difficulty of proving such a philosophical stance.
- Field Bottlenecks and Challenges: Despite a 70x increase in funding over the last decade, the field faces significant hurdles.
- Talent Shortage: A scarcity of researchers is due to the field's historical perception as "sci-fi" or "weird," which deters high-quality candidates despite the presence of competent, rigorous science.
- Data Access: There is a critical lack of access to aged human neural tissue and a scarcity of aged mice for research due to the logistical difficulty and cost of maintaining aged colonies.
- Clinical Trial Design: Demonstrating lifespan extension in humans requires decades-long trials; the field is currently searching for valid biomarkers or intermediate endpoints that correlate with longevity to accelerate approval.
- Funding Imbalance: Aging research is often subsumed under specific disease categories (e.g., Alzheimer's), causing researchers to frame general aging work through disease-specific lenses rather than addressing aging as a primary root cause.
- Key Research Areas: Deming highlights specific biological pathways and mechanisms currently under investigation.
- Nutrient Sensing: Pathways like insulin/IGF-1 and mTOR are central to lifespan regulation; dietary interventions like methionine restriction show similar effects to caloric restriction.
- Mitochondrial Function: Mutations in mitochondria (the cell's powerhouses) are linked to lifespan changes.
- Brain Aging: Research suggests the brain may control systemic aging via temperature regulation and hormonal signaling, though the blood-brain barrier complicates therapeutic intervention.
- Organ Replacement: Theoretical exploration exists for replacing aged organs with younger ones, though immune compatibility and surgical complexity remain major barriers.
- Personal Motivation and Philosophy: Deming's drive is rooted in a rational approach to medicine and emotional responses to premature death.
- Rationality: She views aging as a class of symptoms that has been arbitrarily ignored by the medical establishment, similar to how diseases once thought "inevitable" are now treated.
- Emotional Driver: The inability to prevent the premature death of loved ones (e.g., the animator Satoshi Kan) serves as a primary emotional motivation, distinguishing her work from fear-based motivations.
- Game Theory: She posits that longer lifespans could fundamentally shift societal dynamics toward greater cooperation, as the "number of moves" in human interactions becomes effectively infinite.
- Identity: Deming reflects on the "continuity of consciousness" as a core value, arguing that biological longevity preserves the self more reliably than hypothetical digital uploads.